ルイジアナ州における多発性骨髄腫の臨床試験
ルイジアナ州内の拠点で、多発性骨髄腫に関する9件の研究が参加者を募集しています。
ルイジアナ州内の都市
公式研究テキスト（英語）
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Local Institution - 0385, Shreveport
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT05519085A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- LSU Health Feist Weiller Cancer Center, Shreveport
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07518186Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
- Mary Bird Perkins Cancer Center, Baton Rouge
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07609940A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- LSUHSC Shreveport Feist-Weiller Cancer Center, Shreveport
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05552222A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Pontchartrain Cancer Center, Covington
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/24更新 · NCT07477587A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Louisiana State University Health Sciences Shreveport, Shreveport
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT06615479A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Baton Rouge
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT07227311Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Baton Rouge
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/14更新 · NCT07764978A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Tulane University School of Medicine /ID# 251204, New Orleans
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/13更新 · NCT05650632ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。